TScan Therapeutics, Inc. (TCRX )
Currency in USD Disclaimer
Subscribe Now for Delta3 AI Alerts
Don’t miss out on top stock picks and market insights. Subscribe to Delta3 AI Alerts for real-time updates and expert analysis straight to your inbox. Stay informed and maximize your investment potential.
Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
- Symbol TCRX
- Company TScan Therapeutics, Inc.
- Price $0.24
- Changes Percentage -0.04
- Change -0.0001
- Day Low $0.23
- Day High $0.25
- Year High $2.57
- Year Low $0.29
- Market Cap $21,314,906
- Price Avg 50 EMA (D) $0.66
- Price Avg 200 EMA (D) $0.96
- Exchange NASDAQ
- Volume 606,687
- Average Volume 864,793
- Open $0.24
- Previous Close $0.24
- EPS -0.91
- PE -0.38
- Earnings Announcement 2026-11-11 12:00:00
- Shares Outstanding $61,074,229
Company brief: TSCAN THERAPEUTICS, INC. (TCRX )
- Healthcare
- Biotechnology
- Dr. Gavin MacBeath Ph.D.
- https://www.tscan.com
- US
- N/A
- 07-16-2021
- US89854M1018
TScan Therapeutics, Inc., a preclinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell therapies for the treatment of patients with cancer. It is developing TSC-100 and TSC-101 for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation; and TSC-200, TSC-201, TSC-202, TSC-203, and TSC-204 for the treatment of solid tumors. The company is also developing vaccines for infectious diseases, such as SARS-CoV-2. It has a collaboration and license agreement with Novartis Institutes for BioMedical Research, Inc., to identify novel cancer antigens from the T cells of patients with a certain specific type of cancer. TScan Therapeutics, Inc. was incorporated in 2018 and is headquartered in Waltham, Massachusetts.